Nguyên Nhân Thần Kinh Của Tình Trạng Giảm Hoạt Động Cơ Bàng Quang

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78. Chapple CR, Osman NI, Birder L, et al. The underactive bladder: a new clinical concept? Eur Urol. 2015;68:351–3. Jeong SJ, Kim HJ, Lee YJ, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Kor J Urol. 2012;53:342–8. Abarbanel J, Marcus EL. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology. 2007;69:436–40. Osman NI, Chapple CR. Contemporary concepts in the aetiopathogenesis of detrusor underactivity. Nat Rev Urol. 2014;11:639–48. Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn. 2010;29:408–12. Miyazato M, Yoshimura N, Chancellor MB. The other bladder syndrome: underactive bladder. Rev Urol. 2013;15:11–22. Frimodt-Moller C, Cystopathy D. A review of the urodynamic and clinical features of neurogenic bladder dysfunction in diabetes mellitus. Dan Med Bull. 1978;25:49–60. Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int. 1999;84:14–5. Lim C, Abrams P. The Abrams-Griffiths nomogram. World J Urol. 1995;13:34–9. Schafer W. Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach to grading obstruction: from complex to simple. World J Urol. 1995;13:47–58. Oelke M, Rademakers KL, van Koeveringe GA, et al Unraveling detrusor underactivity: development of a bladder-outlet resistance—bladder contractility nomogram for adult male patients with lower urinary tract symptoms. Neurol Urodyn 2015; PMID:26235823 Drake MJ, Williams J, Bijos DA. Voiding dysfunction due to detrusor underactivity: an overview. Nat Rev Urol. 2014;11:454–64. This article is an excellent overview of the multiple etiologies of DU, the current limitations in treatment, and potential therapeutic targets that have recently been identified to help patients with this condition. Chancellor MB, Kaufman J. Case for pharmacotherapy development for underactive bladder. Urology. 2008;72:966–7. Yu Z, Li J, Li Z, et al Photoselective vaporization of the prostate and simultaneous suprapubic cystostomy for the treatment of benign prostatic hyperplasia in patients with mild to severe detrusor underactivity. Urol Int 2015; PMID:26138113. Krishnamoorthy S, Kekre NS. Detrusor underactivity: to tone or not to tone the bladder? Indian J Urol. 2009;25:407–8. Liu CW, Attar KH, Gall A, et al. The relationship between bladder management and health-related quality of life in patients with spinal cord injury in the UK. Spinal Cord. 2010;48:319–24. Arrellano-Valdez F, Urrutia-Osorio M, Arroyo C, et al. A comprehensive review of urologic complications in patients with diabetes. Springerplus. 2014;3:549. Nirmal J, Tyagi P, Chuang YC, et al. Functional and molecular characterization of hyposensitive underactive bladder tissue and urine in streptozotocin-induced diabetic rat. PLoS One. 2014;9:e102644. Sasaki K, Yoshimura N, Chancellor MB. Implications of diabetes mellitus in urology. Urol Clin North Am. 2003;30:1–12. Yoshimura N, Chancellor MB, Andersson KE, et al. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int. 2005;95:733–8. Fedele D. Therapy insight: sexual and bladder dysfunction associated with diabetes mellitus. Nat Clin Pract Urol. 2005;2:282–90. Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237:1154–62. Sasaki K, Chancellor MB, Goins WF, et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes. 2004;53:2723–30. Manack A, Motsko SP, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims database. Neurourol Urodyn. 2011;30:395–401. Cruz CD, Coelho A, Antunes-Lopes T, et al. Biomarkers of spinal cord injury and ensuing bladder dysfunction. Adv Drug Deliv Rev. 2015;82–83:153–9. Lapides J, Diokno AC, Silber SJ, et al. Clean intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107:458–61. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci. 2006;29:507–38. Vizzard MA. Neurochemical plasticity and the role of neurotrophic factors in bladder reflex pathways after spinal cord injury. Prog Brain Res. 2006;152:97–115. Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol. 2010;12:e69–77. Song QX, Chermansky CJ, Birder LA, et al. Brain-derived neurotrophic factor in urinary continence and incontinence. Nat Rev Urol. 2014;11:579–88. Frias B, Santos J, Morgado M, et al. The role of brain-derived neurotrophic factor (Bdnf) in the development of neurogenic detrusor overactivity (NDO). J Neurosci. 2015;35:2146–60. Ren J, Chew DJ, Biers S, et al. Electrical nerve stimulation to promote micturition in spinal cord injury patients: a review of current attempts. Neurourol Urodyn 2015; PMID:2566315. Brindley GS. An implant to empty the bladder or close the urethra. J Neurol Neurosurg Psychiatry. 1977;40:358–69. Brindley GS, Polkey CE, Rushton DN. Sacral anterior root stimulators for bladder control in paraplegia. Paraplegia. 1982;20:365–81. Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010;67:74–84. Corcos J. A urological challenge: voiding dysfunction in multiple sclerosis. Can Urol Assoc J. 2013;7:S181–2. Hinson JL, Boone TB. Urodynamics and multiple sclerosis. Urol Clin North Am. 1996;23:475–81. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999;161:743–57. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. 2003;63:153–66. Araki I, Matsui M, Ozawa K, et al. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003;169:1384–7. Burney TL, Senapati M, Desai S, et al. Acute cerebrovascular accident and lower urinary tract dysfunction: a prospective correlation of the site of brain injury with urodynamic findings. J Urol. 1996;156:1748–50. Kim TG, Chun MH, Chang MC, et al. Outcomes of drug-resistant urinary retention in patients in the early stage of stroke. Ann Rehabil Med. 2015;39:262–7. Kong KH, Young S. Incidence and outcome of post-stroke urinary retention: a prospective study. Arch Phys Med Rehabil. 2000;81:1464–7. Yum KS, Na SJ, Lee KY, et al. Pattern of voiding dysfunction after acute brainstem infarction. Eur Neurol. 2013;70:291–6. Cho HJ, Kang TH, Chang JH, et al. Neuroanatomical correlation of urinary retention in lateral medullary infarction. Ann Neurol. 2015;77:726–33. Ersoz M, Tunc H, Akyuz M, et al. Bladder storage and emptying disorder frequencies in hemorrhagic and ischemic stroke patients with bladder dysfunction. Cerebrovasc Dis. 2005;20:395–9. Kulakli F, Koklu K, Ersoz M, et al. Relationship between urinary dysfunction and clinical factors in patients with traumatic brain injury. Brain Inj. 2014;28:323–7. Chua K, Chuo A, Kong KH. Urinary incontinence after traumatic brain injury: incidence, outcomes and correlates. Brain Inj. 2003;17:469–78. Giannantoni A, Silvestro D, Siracusano S, et al. Urologic dysfunction and neurologic outcome in coma survivors after severe traumatic brain injury in the postacute and chronic phase. Arch Phys Med Rehabil. 2011;92:1134–8. Moody BJ, Liberman C, Zvara P, et al. Acute lower urinary tract dysfunction (LUTD) following traumatic brain injury (Tbi) in rats. Neurourol Urodyn. 2014;33:1159–64. Badr AV, Purohit RS, Skenazy J, et al. A review of lower urinary tract symptoms in patients with Parkinson’s disease. Curr Urol Rep. 2014;15:435. Ransmayr GN, Holliger S, Schletterer, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70:299–303. Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2009;15:81–7. Araki I, Kitahara M, Oida T, et al. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164:1640–16433. Liu Z, Uchiyama T, Sakakibara R, et al. Underactive and overactive bladders are related to motor function and quality of life in Parkinson’s disease. Int Urol Nephrol. 2015;47:751–7. Campeau L, Soler R, Andersson KE. Bladder dysfunction and Parkinsonism: current pathophysiological understanding and management strategies. Curr Urol Rep. 2011;12:396–403. Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the Parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140:117–8. Roth B, Studer UE, Fowler CJ, et al. Benign prostatic obstruction and Parkinson’s disease—should transurethral resection of the prostate be avoided? J Urol. 2009;181:2209–13. Fowler CJ, Kirby RS. Abnormal electromyographic activity (decelerating burst and complex repetitive discharges) in the striated muscle of the urethral sphincter in 5 women with persisting urinary retention. Br J Urol. 1985;57:67–70. Fowler CJ, Christmas TJ, Chapple CR, et al. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? 1988; 297:1436-1438. Smith PP, Tyagi P, Kuchel GA, et al. Advanced therapeutic directions to treat the underactive bladder. Int Urol Nephrol. 2014;46 Suppl 1:S35–44. This article is an excellent review of the potential therapeutic targets to improve detrusor contractility in patients with DU. Bougas DA, Mitsogiannis IC, Mitropoulos DN, et al. Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor. Int Urol Nephrol. 2004;36:507–12. Witsell DL, Stinnett S, Chambers MS. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia. Head Neck. 2012;34:1136–42. Cardenas DD, Ditunno JF, Graziani V, et al. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord. 2014;52:70–6. Wu ZZ, Li DP, Chen SR, et al. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem. 2009;284:36453–61. Maggi CA, Santicioli P, Borsini F, et al. The effect of 4-aminopyridine on micturition reflex in normal or capsaicin-desensitized rats. Brain Res. 1988;449:61–70. Pataky Z, Gasteyger C, Ziegler O, et al. Efficacy of rimonabant in obese patients with binge eating disorder. Experimental and Clinical Endocrinology & Diabetes. German Society of Endocrinology [and] German Diabetes Association 2013; 121:20-26. Dmitrieva N, Berkley KJ. Contrasting effects of win 55212-2 on motility of the rat bladder and uterus. J Neurosci. 2002;22:7147–53. Aizawa N, Wyndaele JJ, Homma Y, et al. Effects of TRPV4 cation channel activation on the primary bladder afferent activities of the rat. Neurourol Urodyn. 2012;31:148–55. Levanovich PE, Diokno A, Hasenau DL, et al. Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study. Int Urol Nephrol. 2015;47:465–7. This case report of a single patient with DU who received intradetrusor injection of muscle-derived stem cells with resultant improvement in voiding function represents an exciting potential regenerative treatment for patients with DU.